According to the latest statistics from Private Equity Ranking Network, as of April 30th, there are 35 private equity funds with assets over ten billion yuan listed among the top ten shareholders in 244 publicly listed companies, with a total shareholding value of 71.644 billion yuan. Among these private equity funds, Gaoyi Asset has shown a strong interest in the pharmaceutical and chemical sectors. For example, Feng Liu increased his holdings in Kanghua Biology and Longbai Group during the first quarter.
Unlike Gaoyi Asset, Ningquan Asset increased its stakes in Shandong Road and Bridge and Zhouming Technology in the first quarter and newly entered Jilin Aodong and other pharmaceutical stocks. In addition, Juming Investment and Ruijun Asset have shown significant interest in the stocks of the technology and manufacturing industries.
Several industry experts have indicated that with the continuous accumulation of positive factors in the A-share market, the current valuation of the healthcare industry is at a bottom region. Influenced by this, along with considering the broad growth potential of technology and high-end manufacturing, numerous investment opportunities are presenting clear structural characteristics.
Take Ruifeng New Material as an example, the company’s latest quarterly report shows that, benefiting from an optimized product structure and increasing market demand, it has achieved double growth in both revenue and net profit. Research and development and production of fine chemical products are the core business of Ruifeng New Material. During the reporting period, the company’s business income reached 714 million yuan, an increase of 14.41% over the same period last year, and the net profit attributable to the parent company increased by 57.77% year-on-year.
Similarly, under Feng Liu’s management, Gaoyi Linshan No. 1 Yuanwang Private Equity Securities Investment Fund newly entered the list of top ten shareholders of Ruifeng New Material and held 10.003 million shares of the company at the end of the first quarter, with a market value of 383 million yuan. Longbai Group, another enterprise in the chemical field, also disclosed in its latest quarterly report the increased holdings by Gaoyi Asset, with the number of shares held increased to 80 million.
Additionally, products managed by Deng Xiaofeng entered Jinhe Industry in the first quarter of this year; the company is a leading enterprise in the substitute sugar industry, holding 6.4 million shares by the end of the first quarter. The pharmaceutical field is not an exception, as Gaoyi Asset increased its holdings in vaccine manufacturer Kanghua Biology and Dongcheng Lian, a leading chain drugstore in the East China region.
Ningquan Asset has shown interest in mining small and mid-cap stocks. Zhouming Technology, as a supplier of LED products with a high proportion of overseas exports, increased its holdings in Ningquan Asset to 14.2499 million shares in its first-quarter report, with a market value of approximately 92 million yuan. This indicates that Zhouming Technology is expected to benefit from the growth in exports.
At the same time, Ningquan Asset also showed certain interest in Shandong Road and Bridge and slightly increased its holdings in the first quarter. Its three products have a total holding of 21.5175 million shares, with a market value of approximately 119 million yuan. Galaxy Securities pointed out that while consolidating its leading position in the provincial market, Shandong Road and Bridge is striving to expand overseas markets, especially in Tanzania, where it has taken on several projects, with revenue from overseas showing growth in 2023.
In the latest developments in the capital market, Ningquan Asset has shown an active investment stance in the pharmaceutical sector. According to the data analysis by Choice, by the end of the first quarter of this year, products of Ningquan Asset added Jilin Aodong to their list of top ten circulating shareholders, with the newly added holding value reaching a significant size of 4.147 million shares. Moreover, the company’s holding in Zhejiang Medicine also increased significantly during the same period, with the combined holding of its two products reaching 9.5663 million shares, an increase of 4.77 million shares from the end of last year.
On the other hand, Juming Investment and Ruijun Asset have shown a strong focus on technology and manufacturing. Disclosure from listed companies reveals that Dong Chengfei, Managing Partner and Chief Research Officer of Ruijun Asset, appeared on the top ten shareholder lists of 3 listed companies at the end of the first quarter. Specifically, Dong Chengfei’s products invested in the civil electrical product manufacturer Bull Group during the first quarter, buying 1.86 million shares, with a market value of 192 million yuan. In the semiconductor sector, Lixin Technology also increased its holding by 1.69 million shares, while also increasing its holding in the leading wood-based activated carbon enterprise Yuanli Shares by 690,000 shares.
Simultaneously, Juming Investment is also actively adjusting its investment portfolio. According to the first quarter report released by Shenghong Technology, the Juming Rui Instrument Private Equity Securities Investment Fund operated by Juming Investment has become one of the company’s top ten circulating shareholders, holding 4.89 million shares at the end of the period, with a market value of 118 million yuan. Hengmingda’s first-quarter report also revealed that two products of Juming Investment have newly appeared on the company’s top ten shareholder list, holding a total of 3.956 million shares.
Furthermore, during the first quarter of this year, the investment community witnessed the new entries of several other products: Lin Yuan Investment’s products joined the shareholder list of the power equipment enterprise Jinlong Feather, He Yuan Fund entered Haixing Power and Zhiou Technology, and Renqiao Asset made a new investment in Guotou Intelligent.
